Last reviewed 2026-04-20 · How we verify

DAPTACEL™

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Seizures
• Whole limb swelling
• Infantile spasms

Serious adverse events

• Seizures
• Whole limb swelling with generalized symptoms
• Infantile spasms

Key clinical trials

• Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children (PHASE2)
• Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) (PHASE3)
• Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
• Post Marketing Surveillance for ADACEL™ in South Korea (PHASE4)
• Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ (PHASE4)
• Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
• Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DAPTACEL™ CI brief — competitive landscape report
• DAPTACEL™ updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI